Compugen Ltd. · NASDAQ:CGEN
Compugen — Investor Presentation (March 2006)
24 slides from Compugen's investor presentation, March 2006
Slide 1: The Drug and Diagnostic Discovery Company
The Drug and Diagnostic Discovery Company
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words like "may," "expects," "believes," and "intends," and describe opinions about future events. These forward-looking
Slide 3: Compugen Ltd
Compugen Ltd Objective: To be a world leader in drug and diagnostic discovery Competitive Advantage: Development and use of discovery engines based on pioneering efforts in predictive biology Business Model: Primarily licensing out on milestone and revenue sharing basis – Individual molecules – Pipe
Slide 4: What We Do
What We Do • Develop accurate models of the human genome and proteome – More proteins, better annotation • Create technologies to mine the data in search of attractive candidates – Therapeutic proteins, biomarkers, … • Validate the predictions experimentally • Develop as far as necessary and out- li
Slide 5: The Team
The Team • Unique, multi-disciplinary • Almost a decade creating scientific and technical infrastructure and IP • Truly integrated Physicists Mathematicians MDs Molecular Biologists Computer Scientists Biochemists
Slide 6: Experimental Biology: In-House Wet Lab
Experimental Biology: In-House Wet Lab RU 800 700 600 500 Resp. Diff. 400 300 200 100 0 -100 0 100 200 300 400 500 600 Time • Molecular Biology • Cell-based assays T23675 on colon panel 25 MA fold intensity • Protein expression 20 MA fold ratio fold overexpression Q-PCR fold 15 10 5 • Protein purifi
Slide 7: Computational Biology: Key Focus to Date - LEADS
Computational Biology: Key Focus to Date - LEADS • Sophisticated modeling of biological phenomena • State-of-the-art modeling of the human transcriptome and proteome • Proprietary algorithms used to analyze a wide variety of data sources and types • Results drive experimental efforts – “Predictive B
Slide 8: Computational Biology
Computational Biology The LEADS Platform: • Commercial recognition
Slide 9: Computational Biology
Computational Biology The LEADS Platform: • Commercial recognition • Validated via scientific breakthroughs
Slide 10: The Science: Alternative Splicing
The Science: Alternative Splicing Widespread Alternative Splicing in Humans Genome Res. July 2003 Trends in Genetics, Feb. 2004 Science, May 2003 Molecular Cell, April 2004
Slide 11: The Science: Endogenous Antisense
The Science: Endogenous Antisense Thousands of human antisense gene pairs TIBS, Feb. 2004 Trends in Genetics, Oct. 2005 April 2003
Slide 12: The Science: RNA Editing
The Science: RNA Editing Over 12,000 A-to-I RNA Editing Sites August 2004 February 2005
Slide 13: The Science: Processed Pseudogenes, TMG
The Science: Processed Pseudogenes, TMG PNAS – January 2006 Genome Research – Dec. 2005
Slide 14: Bottom Line
Bottom Line Predicted Transcriptome and Proteome “Hunting ground” for intellectual property • Therapeutic peptides and proteins • Targets for antibody therapeutics • Targets for small molecules • Diagnostics and other biomarkers
Slide 15: Discovery Engines: Therapeutic Proteins
Discovery Engines: Therapeutic Proteins Predicted Transcriptome and Proteome SVs of known TPs Secreted forms of receptors Agonists Special cases IP/FTO Cell-based In-vivo Novelty Validation Candidates
Slide 16: Therapeutics: Current status
Therapeutics: Current status • Dozens of drug candidates selected for further evaluation – Various cancers – Immune-related diseases • On-going experimental validation • By year end 2006: – Completed validation efforts – Begun Licensing activities
Slide 17: Discovery Engines: Biomarkers
Discovery Engines: Biomarkers Predicted Transcriptome and Proteome Tissue Specific Disease Associated Antigen SVs of Known Markers Public Microarray Data IP/FTO Microarrays Q-RT-PCR ELISA Novelty In Vitro Validation Candidates
Slide 18: Biomarkers: Status
Biomarkers: Status • To date ~40 candidates successfully validated at the RNA level – Approx. 30 Immunoassay candidates – Approx. 10 NAT candidates • Main fields to date: cancer, cardiovascular disease • New fields: Diabetes type I/II, Stroke, autoimmune diseases (e.g., Rheumatoid Arthritis)
Slide 19: Biomarkers: Commercial Status
Biomarkers: Commercial Status • Early 2004: Decision to develop engines for immunoassay diagnostics • April 2004: Initial discoveries, mRNA validation • August 2004: DPC agreement • June 2005: Biosite agreement • June 2005: Ortho (J&J) agreement • December 2005: Multiple candidates selected by partn
Slide 20: Business Model
Business Model • License discoveries to leading partners in their respective fields – single molecule – multiple candidates (“pipeline” agreements) • Development costs by partners • Milestone payments/revenue sharing on sales of end products to Compugen • Agreements cover: – existing candidates in I
Slide 21: Financial Status: Cash Flow and Shares
Financial Status: Cash Flow and Shares (in millions) 2004 2005 Cash beginning of year $60.5 $48.4 Sources $8.2 $3.9 Uses ($20.3) ($15.5) Net “Cash Burn” ($12.1) ($11.6) Cash end of period $48.4 $36.8 Long-term debt none none Fully diluted shares 31.9 32.6
Slide 22: Two Year Commercial Roadmap
Two Year Commercial Roadmap 2006 2007 Q4 ‘05 Q1 ‘06 Q2 ‘06 Q3 ‘06 Q4 ‘06 Q1 ‘07 Q2 ‘07 Q3 ‘07 Q4 ‘07 Therapeutic In-Vitro In-Vivo Licensing Activities Proteins E n Diagnostics: Partner Validation Product Development g Immunoassay i n Diagnostics: Candidate e Nucleic-Acid Licensing Activities Partner
Slide 23: In Summary
In Summary • Proven Leader in “predictive biology” – Unique capabilities – Deeper understandings of significant biological phenomena • Focusing efforts via specific discovery engines – “Discoveries on demand” – Growing IP portfolio • Licensing out of discoveries – Partners invest in development and
Slide 24: www.cgen.com
www.cgen.com The Drug and Diagnostic Discovery Company